Progenics Pharmaceuticals (NASDAQ:PGNX) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Thursday.
A number of other analysts also recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 target price on shares of Progenics Pharmaceuticals in a research note on Tuesday, September 5th. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a research note on Friday, September 1st. Finally, Aegis reaffirmed a “buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a research note on Tuesday, August 22nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $13.75.
Shares of Progenics Pharmaceuticals (PGNX) traded up $0.43 on Thursday, hitting $5.98. The company’s stock had a trading volume of 943,980 shares, compared to its average volume of 1,069,045. Progenics Pharmaceuticals has a twelve month low of $4.60 and a twelve month high of $11.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.86 and a quick ratio of 7.86.
Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. The business had revenue of $2.70 million during the quarter, compared to the consensus estimate of $3.58 million. During the same period last year, the company earned $0.52 EPS. The company’s revenue for the quarter was down 95.0% on a year-over-year basis. sell-side analysts forecast that Progenics Pharmaceuticals will post -0.92 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PGNX. Piedmont Investment Advisors LLC purchased a new position in shares of Progenics Pharmaceuticals during the 2nd quarter worth $103,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Progenics Pharmaceuticals during the 2nd quarter worth $108,000. Municipal Employees Retirement System of Michigan grew its holdings in shares of Progenics Pharmaceuticals by 4.0% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 16,600 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 640 shares during the period. LS Investment Advisors LLC grew its holdings in shares of Progenics Pharmaceuticals by 473.8% during the 2nd quarter. LS Investment Advisors LLC now owns 16,897 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 13,952 shares during the period. Finally, Aperio Group LLC purchased a new position in shares of Progenics Pharmaceuticals during the 3rd quarter worth $118,000. Institutional investors and hedge funds own 84.64% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/08/progenics-pharmaceuticals-pgnx-upgraded-to-hold-at-valuengine.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.